InMode Ltd (STU:154)
€ 16.81 0.21 (1.27%) Market Cap: 1.24 Bil Enterprise Value: 587.59 Mil PE Ratio: 9.22 PB Ratio: 1.77 GF Score: 64/100

Inmode Ltd at UBS Genomics 2.0 and MedTech Innovations Summit Transcript

Aug 15, 2023 / 04:00PM GMT
Release Date Price: €36.96 (+0.27%)
Danielle Joy Antalffy
UBS Investment Bank, Research Division - Analyst

All right, everyone. Well, thank you for joining us for our second panel of the day, fireside chat with a company I cover. I'm new to InMode and have had a fun time getting to know them. We have CFO, Yair Malca, with us. Thank you so much, Yair, for making the very long 30-minute drive here.

Questions & Answers

Danielle Joy Antalffy
UBS Investment Bank, Research Division - Analyst

So maybe let's start with a brief introduction into InMode, how the product is different, how your product offering is differentiated and your approach to R&D, sales and marketing, all of that. What's the TAM, the competitive landscape? And we'll go from there. That's a lot. That will take 45 minutes.

Yair Malca
InMode Ltd. - CFO

Danielle, thanks for having me. InMode is the leading aesthetic medical device company. And we also started expanding to what we call wellness in the last couple of years. Our main focus is radio frequency-based technology and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot